ScreenerHero

NKTX Nkarta, Inc.

NAS · US · Healthcare · Biotechnology · nkartatx.com
2.270USD-1.73%Mkt Cap: 162.59M $P/E: —

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen re…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap162.59M USD
Enterprise Value56.23M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-104.08M USD
Revenue/Share—
Last Price2.270 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees106
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.32
PEG—
EV/EBITDA-0.50
EV/Revenue—
P/S—
P/B0.67
EPS (TTM)-1.44
EPS (Forward)-1.75
52W Range
1.70028% of range3.715
52W High3.715 USD
52W Low1.700 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-33.33%
ROA-25.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.70M USD
CapEx (TTM)1.21M USD
FCF Margin—
FCF Yield-33.91%
Net Debt-109.22M USD
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity0.24
Current Ratio7.98
Quick Ratio7.85
Book Value/Sh3.46 USD
Cash/Share2.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.83 USD
Upside (mean)+377.2%
Target Range9.000 USD – 14.00 USD
9.000+377.2% to mean14.00
# Analysts6
Ownership
Shares Out.71.62M
Float60.52M
Insiders4.88%
Institutions82.88%
Short Interest
Short Ratio6.1d
Short % Float6.12%
Short % Out.4.90%
Shares Short3.51M
Short (prev mo.)3.60M
Technical
SMA 502.595 (-12.5%)
SMA 2002.535 (-10.4%)
Beta0.94
S&P 52W Chg16.45%
Avg Vol (30d)606.29K
Avg Vol (10d)603.15K
Technical Indicators
RSI (14)33.2
MACD-0.0717
MACD Signal-0.0035
MACD Hist.-0.0681
BB Upper3.197 USD
BB Middle2.742 USD
BB Lower2.287 USD
BB Width33.17%
ATR (14)0.1718 USD
Vol Ratio (20d)0.89x